ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -87.87M | -80.20M | -73.09M | -- | -- |
| Total Depreciation and Amortization | 2.64M | 2.53M | 2.33M | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.22M | 3.17M | 3.24M | -- | -- |
| Change in Net Operating Assets | -7.31M | 326.82M | 329.81M | -- | -- |
| Cash from Operations | -88.32M | 252.31M | 262.29M | -- | -- |
| Capital Expenditure | -1.89M | -2.52M | -2.94M | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.91M | -201.39M | -206.99M | -- | -- |
| Cash from Investing | 81.02M | -203.91M | -209.93M | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 22.00K | 99.00K | 97.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 22.00K | 99.00K | 97.00K | -- | -- |
| Foreign Exchange rate Adjustments | 119.00K | 90.00K | 23.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.16M | 48.59M | 52.48M | -- | -- |